Ashish R Kumar

Summary

Affiliation: Cincinnati Children's Hospital Medical Center
Country: USA

Publications

  1. pmc t(4;11) leukemias display addiction to MLL-AF4 but not to AF4-MLL
    Ashish R Kumar
    Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA
    Leuk Res 35:305-9. 2011
  2. pmc A role for MEIS1 in MLL-fusion gene leukemia
    Ashish R Kumar
    Masonic Cancer Center, Minneapolis, MN 55455, USA
    Blood 113:1756-8. 2009
  3. pmc Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells
    Weili Chen
    University of Minnesota Cancer Center, University of Minnesota, 420 Delaware Street S E, Minneapolis, MN 55455, USA
    Cancer Cell 13:432-40. 2008
  4. ncbi request reprint Hoxa9 influences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia
    Ashish R Kumar
    Department of Pediatrics, University of Minnesota, Minneapolis, USA
    Blood 103:1823-8. 2004
  5. ncbi request reprint FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases
    Qing Yao
    University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA
    Clin Cancer Res 9:4483-93. 2003

Collaborators

  • Qing Yao
  • Baolin Wu
  • Weili Chen
  • Thien N Sam
  • Quanzhi Li
  • Rodney A Staggs
  • Erik A Lund
  • Wendy A Hudson
  • John H Kersey

Detail Information

Publications5

  1. pmc t(4;11) leukemias display addiction to MLL-AF4 but not to AF4-MLL
    Ashish R Kumar
    Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA
    Leuk Res 35:305-9. 2011
    ..Overall, these results demonstrate that in t(4;11) leukemia, the MLL-AF4 fusion protein is critical for leukemia cell proliferation and survival while the AF4-MLL fusion product is dispensable...
  2. pmc A role for MEIS1 in MLL-fusion gene leukemia
    Ashish R Kumar
    Masonic Cancer Center, Minneapolis, MN 55455, USA
    Blood 113:1756-8. 2009
    ..Targeting MEIS1 may have therapeutic potential for treating leukemias expressing this transcription factor...
  3. pmc Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells
    Weili Chen
    University of Minnesota Cancer Center, University of Minnesota, 420 Delaware Street S E, Minneapolis, MN 55455, USA
    Cancer Cell 13:432-40. 2008
    ..Mll-AF9 upregulated expression of 192 genes in both LSK and progenitor cells, but to higher levels in LSKs than in committed myeloid progenitors...
  4. ncbi request reprint Hoxa9 influences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia
    Ashish R Kumar
    Department of Pediatrics, University of Minnesota, Minneapolis, USA
    Blood 103:1823-8. 2004
    ..Instead, we propose that the "Hox code" minimally defined by the Hoxa5-a9 cluster is central to MLL leukemogenesis...
  5. ncbi request reprint FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases
    Qing Yao
    University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA
    Clin Cancer Res 9:4483-93. 2003
    ..We conducted studies to evaluate the hypothesis that FLT3 is a client of heat shock protein (Hsp) 90 and inhibitors of Hsp90 may be useful for therapy of leukemia...